SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+3.98%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$741M
AUM Growth
+$741M
(+15%)
Cap. Flow
+$156M
Cap. Flow
% of AUM
21.02%
Top 10 Holdings %
Top 10 Hldgs %
44.76%
Holding
95
New
21
Increased
23
Reduced
18
Closed
26
Top Buys
| 1 |
FibroGen
FGEN
|
$21.9M |
| 2 |
Smith & Nephew
SNN
|
$20.5M |
| 3 |
APEN
Apollo Endosurgery, Inc.
APEN
|
$19.3M |
| 4 |
Lantheus
LNTH
|
$15.5M |
| 5 |
CVS Health
CVS
|
$14.2M |
Top Sells
| 1 |
FLXN
Flexion Therapeutics, Inc.
FLXN
|
$12.7M |
| 2 |
NeoGenomics
NEO
|
$9.19M |
| 3 |
CareDx
CDNA
|
$8.03M |
| 4 |
Cytosorbents Corp
CTSO
|
$6.5M |
| 5 |
C4 Therapeutics
CCCC
|
$6.1M |
Sector Composition
| 1 | Healthcare | 95.46% |
| 2 | Financials | 0.86% |
| 3 | Consumer Staples | 0% |
| 4 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
CVRx
CVRX
$204M
| $11.8M | 1.18% |
962,165
+343,100
| +55% | +$4.2M |
|
27
Evolus
EOLS
$477M
| $8.2M | 0.82% |
1,258,889
+615,955
| +96% | +$4.01M |
|
28
Xilio Therapeutics
XLO
$37.5M
| $7.64M | 0.76% |
+477,495
| New | +$7.64M |
|
29
Vaxcyte
PCVX
$4.17B
| $7.01M | 0.7% |
294,750
-60,900
| -17% | -$1.45M |
|
|
SIEN
30
DELISTED
Sientra, Inc.
SIEN
| $6.94M | 0.7% |
189,188
-49,418
| -21% | -$1.81M |
|
31
Inspire Medical Systems
INSP
$2.53B
| $6.32M | 0.63% |
27,450
-3,500
| -11% | -$805K |
|
32
Bioventus
BVS
$471M
| $6.21M | 0.62% |
428,397
+333,795
| +353% | +$4.84M |
|
33
Pacira BioSciences
PCRX
$1.22B
| $6.11M | 0.61% |
101,600
+35,600
| +54% | +$2.14M |
|
34
Galapagos
GLPG
$2.06B
| $5.45M | 0.55% |
98,800
-16,500
| -14% | -$910K |
|
|
TVRD
35
Tvardi Therapeutics, Inc. Common Stock
TVRD
$270M
| $5.2M | 0.52% |
+11,867
| New | +$5.2M |
|
36
Y-mAbs Therapeutics
YMAB
$390M
| $5.03M | 0.5% |
310,494
+44,794
| +17% | +$726K |
|
|
KDNY
37
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $4.87M | 0.49% |
+298,700
| New | +$4.87M |
|
38
Baxter International
BAX
$12.1B
| $4.38M | 0.44% |
+51,000
| New | +$4.38M |
|
39
IO Biotech
IOBT
$115M
| $4.31M | 0.43% |
+672,734
| New | +$4.31M |
|
40
DexCom
DXCM
$30.9B
| $4.17M | 0.42% |
+31,036
| New | +$4.17M |
|
41
Dyne Therapeutics
DYN
$1.92B
| $4.03M | 0.4% |
338,760
+160,400
| +90% | +$1.91M |
|
42
AbbVie
ABBV
$374B
| $3.72M | 0.37% |
+27,500
| New | +$3.72M |
|
|
ARNA
43
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $3.72M | 0.37% |
40,000
-16,800
| -30% | -$1.56M |
|
|
CUTR
44
DELISTED
Cutera, Inc.
CUTR
| $3.56M | 0.36% |
86,180
+71,700
| +495% | +$2.96M |
|
|
DALS
45
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
| $3.43M | 0.34% |
350,000
| – | – |
|
46
Verastem
VSTM
$585M
| $3.37M | 0.34% |
+137,042
| New | +$3.37M |
|
|
ARYD
47
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
| $2.98M | 0.3% |
300,000
| – | – |
|
|
ZGNX
48
DELISTED
Zogenix, Inc.
ZGNX
| $2.85M | 0.28% |
175,152
+4,152
| +2% | +$67.5K |
|
|
PVLA
49
Palvella Therapeutics, Inc. Common Stock
PVLA
$592M
| $2.6M | 0.26% |
8,593
-657
| -7% | -$199K |
|
50
Vanda Pharmaceuticals
VNDA
$279M
| $2.49M | 0.25% |
158,700
-139,900
| -47% | -$2.2M |
|